Introduction
Anaplastic large-cell lymphoma (ALCL) accounts for only 10%-15% of all childhood non-Hodgkin's lymphomas [1, 2] . Like the other childhood lymphomas, ALCL are highly chemo-sensitive with complete remission rates ranging from 66%-100% with various multiagent chemotherapy regimens in adult [3] [4] [5] [6] [7] [8] [9] [10] [11] and childhood [12] [13] [14] [15] series. However, in most of the series, 20%-40% of the patients develop recurrent disease. As the disease is rare, reports on the treatment and outcome of ALCL relapses are limited in number and usually concern small series of patients [4-6, 13, 15] . Furthermore, the second-line treatment is often heterogeneous and followup usually short. Data concerning treatment intensification with bone marrow or stem-cell transplantation (BMT) for ALCL relapses are also limited and heterogeneous with respect to the status of the disease at the time of BMT and to conditioning regimens [16] [17] [18] [19] [20] . This study analyses the outcome of 41 children treated in France for a relapsed ALCL between 1975 and 1997.
Patients and methods

Patients
We analysed the data on all consecutive relapses that occurrred in three series of patients treated for ALCL between 1975 and 1997. The first group of patients were first diagnosed as having malignant histiocytosis which, after review of histopathologic material, were reclassified as ALCL. They were treated between 1975 and 1988 with the COPAD protocol in the Pediatrics department at the Institute Gustave Roussy [21] . The second and third series of patients were treated at several institutions of the French Society of Pediatric Oncology (SFOP) and enrolled in two multicentric prospective SFOP studies, HM89 and HM91 for newly diagnosed childhood ALCL [22] . Of the 119 patients included in these 3 series, 41 children relapsed and they constitute the study population. The main patient characteristics are shown in Table 1 .
The histopathologic material was reviewed in the reference laboratory for the HM studies for the 41 patients included in the study. The diagnosis of ALCL was based on the morphologic and immunologic criteria of the R.E.A.L. Classification for non-Hodgkin's lymphomas [23] . The positivity for B-cell markers excluded the diagnosis of ALCL. Immunohistochemistry was performed on routine sections and on frozen sections, when available, by applying a panel of monoclonal and polyclonal antibodies [24] , 
Statistical analysis
Overall survival rates were estimated using the Kaplan-Meier method [25] from the date of the first relapse to death or to the date of the last observation for the patients who were still alive. Disease-free survival rates (DFS) were estimated from the date of the first relapse to the time of documented failure (date of the relapse for patients who did not achieve a second CR, the time of the second relapse or the time of death for the others) or to the date of the last observation for those in second CR. Follow-up data were updated on 1 March 1998. Statistical differences in DFS were tested by the two-tailed log-rank test. As the number of patients included in this study is rather small, only four factors were tested in univariate analysis: recurrence occurring during or after treatment, time to relapse less or more than 12 months, firstline treatment and ABMT in CR2.
First-line treatment
The first group of patients were treated with a 12-18-month chemotherapy regimen combining vincristine, doxorubicin, cyclophosphamide, prednisone and intrathecal methotrexate [21] . For the second and third groups of patients, the same drugs were combined with highdose methotrexate and etoposide for the HM89 protocol and with high-dose methotrexate, etoposide, bleomycin and vinblastine in the HM91 protocol [22] . The duration of the treatment was seven to eight months for these latter groups. No patient had high-dose chemotherapy with autologous bone marrow transplantation at first complete remission (CR) except for one in the HM91 series whose disease progressed during first-line treatment
Second-line treatment
The second-line chemotherapy protocols were somewhat heterogeneous since the choice of the treatment for relapse was left to each center. However, in the first two series of patients, the protocol suggested for relapses was the CVBA, combination which had previously been tested for relapsed lymphoma in the Pediatrics department at Institut Gustave Roussy ( Table 2 ). The treatment suggested for relapses for the HM91 series, was CVA (Table 2) . Intensification with a high-dose regimen and autologous bone marrow (or peripheral stem cell) transplantation (ABMT) was strongly recommended for patients in second remission (CR2) in this third series.
Results
First relapses
Overall, 36 of 41 patients achieved a CR. One patient is not evaluable for response to second-line chemotherapy since he underwent resection of the entire tumor mass for the diagnosis of the relapse before the beginning of chemotherapy. Among the 40 patients who are evaluable for response, 35 (88%) achieved a CR following various chemotherapy regimens: 25 with CVA or CVBA, 2 with high-dose ara-C VP16 according to the CYVE protocol [26] , 3 with vinblastine and 5 with other regimens. Five patients did not achieve CR and died of progressive disease seven to twenty-two months after the first relapse (median 16 months). The CR rate did not vary significantly according to the first-line chemotherapy previously used. It was 92% (11 of 12) for patients treated with COPAD, 88% ( 
Second, third and further relapses
Overall, 10 of 15 patients achieved a CR3 with various regimens, 3 were treated with local radiation therapy and 3 others underwent ABMT while in CR3. Five patients did not achieve a CR and died. Among the 10 patients who achieved a CR3, 5 had a third relapse including 2/3 patients treated with radiotherapy and 2/3 patients who had received ABMT in CR3.
Overall, among the patients who relapsed twice, 6 died and 9 are alive in third (5 patients), fourth (2 patients), fifth (1 patient) and sixth remission (1 patient) with a median follow-up of 40 months (10 months -7 years) since the last relapse. These nine long-term survivors do not differ from the overall population in terms of the duration of the first remission and the percentage of exclusively nodal recurrent disease.
Vinblastine treatment
It is noteworthy that 12 patients were treated with weekly vinblastine for 6-18 months for a first (4 patients), second (5 patients), third (1 patient), fifth (2 patients) relapse including 6 relapses which occurred after highdose chemotherapy and ABMT. Vinblastine was given at a dose of 6 mg/m 2 and combined with steroids for 0.5-2 months in two cases. One patient failed to respond and died early and one patient is not evaluable for response since he was in CR after the biopsy and before the beginning of vinblastine. Ten patients achieved a CR following vinblastine treatment (six had only localized nodal involvement and four disseminated disease). Following this CR, 3 patients were given high-dose chemotherapy and ABMT and 8 were treated with vinblastine alone for 6-18 months. Overall, 7 patients (including 4 patients given vinblastine after a relapse from BMT) are alive disease-free and had no further relapse with a follow-up of 10-48 months (median 30 months) since the beginning of vinblastine treatment. Among them, 2 are still on therapy whereas vinblastine treatment has been stopped since 15-36 months (median 27 months) in the other five patients. Only one of these long-term survivors had had ABMT after a remission induced by vinblastine.
Treatment intensification with ABMT
Overall, 15 patients underwent myelo-ablative therapy with BMT in CR2 (2 patients). All but one of these patients had received the HM91 protocol for first-line treatment. Conditioning regimens were heterogeneous and included total body irradiation (TBI) in nine patients, busulfan in three patients and neither TBI nor busulfan in three patients. Fourteen patients had autologous BMTor peripheral stem cell transplantation (PSCT) and one allogeneic BMT. One died of toxicity, five relapsed four to twenty-one months after BMT (median 16 months) and nine are in continuous CR with 2 months to 7.5 years of follow-up (median 18 months) post BMT.
Six other patients underwent myelo-ablative therapy with ABMT in PR2 (two patients), PR3 (one patient) or CR3 (three patients). All 3 patients treated in PR died of disease progression within 10 months after BMTand 2/3 patients treated in CR3 relapsed again.
Among the patients who relapsed post BMT, 6 were treated with low-dose chemotherapy (vinblastine (4 patients), oral methotrexate (1 patient), oral vepeside (1 patient)) and are alive with no evidence of disease 10-52 months after the last relapse (median 44 months).
Survival
Overall, with a median follow-up of 5 years (2 months -21 years), 3 patients died of toxicity, 9 patients died of their disease in first (6 patients), second (3 patients) or a further relapse (1 patient) and 29 patients are alive in CR2 (20 patients), CR3 (5 patients), CR4 (2 patients), CR5 (1 patient) and CR6 (1 patient) (Figure 1 ).
Overall and disease-free survival rates are respectively 69% (53%-82%) and 44% (29%-61%) at three years ( Figure 2 ).
Prognostic factors
In the univariate analysis (Table 3 ) two factors were found to be associated with a higher risk of failure: an interval of less than 12 months between the diagnosis and the relapse and first-line treatment with the HM protocols. On the contrary, the occurrence of the relapse during or after treatment and a treatment including ABMT after a second CR (Figure 3 ) appeared to have no effect on the outcome. 
Discussion
Relapses are not rare events in ALCL patients treated with intensive multiagent regimens [4] [5] [6] [7] [8] [12] [13] [14] [15] . In most of the series reported to date, there is a marked difference between OS and DFS because patients live for prolonged periods after a relapse [4-6, 11, 12, 14] . In all of these referenced reports, the number of patients treated for a relapse was quite small and the treatments were heterogeneous. Moreover, most of the patients reported were treated with megatherapy in second CR. It is therefore difficult to assess the optimal treatment for relapsed ALCL and to estimate the role of megatherapy in these children on the basis of these data. The present study was designed to evaluate the response rate and the long-term outcome of patients treated for recurrent ALCL. As it is a retrospective study spanning over two decades, the treatment modalities, and especially the indications for ABMT, have been subject to considerable changes according to the period. Although riddled with heterogeneity in several respects including the combination of single-institution data with data from a multicentric study, the relapses in these three series of patients allowed a comparison of the results of treatment according to both first-line therapy and second-line treatment.
One of the major results of this study is that it demonstrates the high response rate achieved in patients treated for a recurrent ALCL: over 85% achieved a second CR. This response rate does not appear to have differed according to first-line treatment.
However, more than 40% of the patients who achieved a second CR experienced a second relapse. Nonetheless, the response rate was still quite high in patients treated for multiple relapses and the high percentage of survivors is strikingly different from the results usually reported for relapsed non-Hodgkin's lymphoma since the overall twoyear survival rate of the patients in this combined series is 69% (53%-82%) with a median follow-up of five years.
One of the questions raised by this study is whether consolidation with high-dose regimen and ABMT is efficient in avoiding further relapses in patients who achieve a a CR with second-line treatment. The usefulness of these modalities has been reported for several years for non-Hodgkin's lymphomas at relapse [27] [28] [29] [30] [31] or at first CR for high-risk adult patients [9, 32] . Data concerning the value of this procedure in ALCL are very scarce [9, [16] [17] [18] [19] even-though some authors recommend using ABMT at first CR in adult patients with high-risk ALCL [9, 32, 33] . Recently, Fanin et al. reported a series of 64 patients with ALCL treated with ABMT in 25 centers of the European Group for Blood and Marrow Transplantation (EBMT) [20] . In this study (including several patients of the present study), the 10-year overall survival of the whole population is 70%. However, only 6 of 15 patients transplanted in CR after a relapse maintained the CR over time. In the present study, the three-year DFS of patients treated with ABMT in CR is rather good (45%, 20%-73%). In univariate analysis, it was not, however, statistically different from the DFS of patients treated without ABMT in second CR (52%, 31%-73%). Comparison of the outcome of the patients treated with or without ABMT should, however, be interpreted with caution because the indications for BMT varied according to the treatment period. Patients who did not undergo BMT in second CR were mostly those treated before 1991 with COPAD or the HM89 protocol as first-line treatment whereas almost all the patients who relapsed after HM91 chemotherapy underwent ABMT in second CR. The long-lasting CR obtained with conventional low-dose chemotherapy in six of eight patients who relapsed after BMT also suggests that prolonged conventional chemotherapy might be as efficient as short intensive treatment comprising ABMT in some patients. Whether one conditioning regimen has an edge over another in terms of efficiency cannot be answered in this series given the heterogeneity of the treatments received by the patients. As a major drawback of megatherapy is transplant-related morbidity or mortality in patients who could be cured with conventional treatment, the latter therapy should be preferred for first relapses. However, to evaluate the contribution of ABMT to the treatment of relapsed ALCL, prospective studies will have to be undertaken in high-risk patients, i.e., those who relapse very early or who experience second relapses after failure of prolonged conventional chemotherapy.
An unexpected result of this study was the excellent outcome of children treated with weekly vinblastine. Vinblastine can be administered over extended periods of time because of its low toxicity and in the early sixties, several papers reported prolonged remissions of various malignancies following long-term treatment with weekly vinblastine [34] . The most important results were those reported for Hodgkin's disease, a lymphoma which shares several pathological and clinical aspects with ALCL [35] . In a review published in 1973 [36] , Carter, summarizing 20 previous papers, reported a response rate of 68% in 682 patients treated with vinblastine alone for Hodgkin's disease. More recently, several authors [37, 38] have reported the efficacy of weekly vinblastine for relapsed Hodgkin's disease. In these studies, long-lasting remissions were obtained in heavily pretreated patients, some of whom had undergone bone marrow transplantation [38] . However, in these studies, vinblastine was continuously given until disease progression since the first reports suggested that relapse should occur if maintenance treatment was discontinued [34, 39] . It may not be the case in our study since several patients are in continuous complete remission several months after the end of vinblastine. These results in heavily pretreated patients suggest that maintenance treatment with vinblastine could be useful as first-line treatment in high-risk patients. As ALCL is rare in children, evaluation of the efficacy of such strategies for first-line treatment and of the optimal treatment for relapses will only be possible through large international randomized studies.
